Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This study is currently recruiting participants.
Verified April 2013
by UNC Lineberger Comprehensive Cancer Center
Study NCT01298570 Information provided by UNC Lineberger Comprehensive Cancer Center
First Received on February 16, 2011. Last Updated on April 26, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Colorectal Cancer Metastatic
Additional conditions recognized in this trial
Colorectal Neoplasms
Neoplasms
Neoplasms, Second Primary
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
Regorafenib (BAY 73-4506)
FOLFIRI
Placebo
Additional drug interventions recognized in this trial
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
More general drug interventions related to this trial
Antidotes
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Vitamin B Complex
Vitamins
Sponsors listed in this trial
UNC Lineberger Comprehensive Cancer Center
Bayer
Back to top of Main Content
